The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements. GalXC™ and GalXC-Plus™ are trademarks of Dicerna Pharmaceuticals, Inc. View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005811/en/ CONTACT: Media: Amy Trevvett +1 617-612-6253 : Janhavi Mohite +1 212-362-1200 KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES HEALTH GENETICS PHARMACEUTICAL SOURCE: Dicerna Pharmaceuticals, Inc. Copyright Business Wire 2021. PUB: 09/02/2021 04:05 PM/DISC: 09/02/2021 04:06 PM http://www.businesswire.com/news/home/20210902005811/en